On June 17, 2025, Plus Therapeutics Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, committing Lincoln Park to purchase up to $50 million of the company's common stock. The share price for transactions under this agreement may vary, but the agreement includes provisions for a purchase price per share in an Accelerated Purchase to be 96.5% of the lower of specified market prices. The specific number of shares and exact prices for these transactions were not disclosed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-143665), on June 20, 2025, and is solely responsible for the information contained therein.